HCV infection, B-cell non-Hodgkin’s lymphoma and immunochemotherapy: Evidence and open questions

Table 1 Features and outcome of hepatitis C virus + patients with aggressive B-cell non-Hodgkin’s lymphoma treated with chemotherapy and immunochemotherapy

Author	Year	HCV + patients1	Histology	Study	Therapy	Severe HT (%)	Poor prognostic factors	ORR (%)	PFS	OS
Visco et al[6]	2006	132	DLBCL	Multicenter, retrospective	CHOP-like (85%)	15	Hepatic dysfunction	93	51% (5 yr)	72% (5 yr)
					R-CHOP-like (26%)		HBV co-infection
							High IPI
							Advanced stage
							Nodal origin
Besson et al[13]	2006	26	DLBCL	Case control, retrospective	Intensified CHT, no Rituximab	45	Advanced stage	72	-	56% (5 yr)
							High IPI
Arcaini et al[9]	2010	101	DLBCL	Retrospective series	CHOP-like	15	HCV genotype 1	77	43% (5 yr)	68% (5 yr)
					R-CHOP-like (23%)		HT during CHT
Marignani et al[10]	2011	8	DLBCL = 7	Retrospective series	R-CHOP-like	28	NE	80	70% (4 yr)	80% (4 yr)
			BL = 1
Ennishi et al[11]	2010	131	DLBCL	Retrospective series	R-CHOP-like	27	Hepatic dysfunction	-	69% (3 yr)	75% (3 yr)
							Age
							High IPI
							Advanced stage

¹Number of hepatitis C virus (HCV) + patients treated with curative intent. NE: Not evaluable; PFS: Progression-free survival; OS: Overall survival; HT: Hepatic toxicity; CHT: Chemotherapy; IPI: International Prognostic Index.